AF
GBIO

Amalgamated Financial’s Generation Bio GBIO Stock Holding History

Amalgamated Financial’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$52K Buy
+704
New +$40.8K ﹤0.01% 2410

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

Amalgamated Financial's GBIO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Generation Bio (GBIO) in Q1 2022: 704 shares worth $52K. The stake represents ﹤0.01% of the portfolio and ranks #2410 among its holdings.

88 funds tracked by Wall St. Rank hold GBIO as of Q1 2022.

  • Amalgamated Financial held 704 shares of Generation Bio worth $52K as of Q1 2022.
  • Generation Bio was a new Amalgamated Financial position in Q1 2022.
  • Generation Bio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2410 holding.
  • 88 funds tracked by Wall St. Rank held Generation Bio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.